BLINATUMOMAB

Brand name:

• Blincyto®

Pharmaceutical company:

AMGEN AUSTRALIA PTY LIMITED

Condition/indication:
(therapeutic use)

• Measurable residual disease (MRD)-negative B-cell precursor acute lymphoblastic leukaemia (B-ALL)

PBAC Submission type:

Change to existing listing (Category 2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2024

Related medicines:

• BLINATUMOMAB

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Deferred (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---